Mesoblast (ASX:MSB) shares have delivered standout gains lately, with the stock up 42% over the past month and nearly 70% higher over the past 3 months. Investors seem to be re-evaluating the outlook.

See our latest analysis for Mesoblast.

Mesoblast’s recent share price surge is part of an encouraging turnaround, reflecting shifting sentiment after a rocky period earlier in the year. While momentum has clearly been building in the last few months, the 1-year total shareholder return of 85% shows that long-term investors have started to see substantial gains after an extended period of frustration.

If the strong recovery in Mesoblast has you curious about more opportunities, consider taking your search further and discover fast growing stocks with high insider ownership

With Mesoblast’s share price rallying, the key question is whether the stock remains undervalued at current levels, or if investors have already factored in all the potential future growth. Could there still be a buying opportunity here?

Price-to-Book of 3.9x: Is it justified?

Mesoblast’s current price-to-book ratio of 3.9x sits below both the peer group average of 4.4x and the Australian Biotechs industry average of 4.2x. This makes the shares appear attractively valued against similar companies. At last close, Mesoblast traded at A$2.76, reflecting a discount even as momentum has turned sharply positive in recent months.

The price-to-book ratio compares the market value of a company’s equity to its net assets. For biotech stocks like Mesoblast, where earnings may be volatile or negative due to high R&D expenses, the price-to-book multiple is a widely used yardstick for basic valuation benchmarks.

Given Mesoblast’s uptick in revenue growth forecasts and the fact that its current valuation is below peers, the market may be underestimating the company’s longer-term asset value potential. This discount suggests that investors are not fully pricing in the future growth prospects or a turnaround to profitability that is anticipated by some in the sector.

Compared to the sector, Mesoblast looks undervalued by this measure, especially as its ratio is lower than both the broader biotech group and more direct peers. Investors may be getting more for each dollar of net assets than in comparable companies.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 3.9x (UNDERVALUED)

However, risks remain, including ongoing net losses and the possibility of revenue growth not meeting expectations. These factors could challenge the recent bullish outlook.

Story Continues

Find out about the key risks to this Mesoblast narrative.

Another View: Discounted Cash Flow Perspective

Taking a different approach, the SWS DCF model estimates Mesoblast is trading well below its fair value, with shares currently at a significant discount. This perspective suggests even more upside than the asset-based metric alone might indicate. However, the question remains whether this optimism can be sustained as conditions change.

Look into how the SWS DCF model arrives at its fair value.MSB Discounted Cash Flow as at Oct 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Mesoblast for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Mesoblast Narrative

If you see things differently or want to dig deeper yourself, you can build your own investment narrative in just a few minutes and do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Mesoblast.

Looking for more investment ideas?

Great opportunities don’t stop at Mesoblast. Lock in your next smart move by using these hand-picked screens and tap into market trends others may miss:

Uncover potential market leaders with big yield potential by assessing these 19 dividend stocks with yields > 3% offering attractive returns above 3%. Seize the AI edge and target innovation by reviewing these 31 healthcare AI stocks poised to disrupt the healthcare sector. Catch early-stage momentum and growth possibilities by evaluating these 3561 penny stocks with strong financials with robust financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MSB.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments